# Antigen and adjuvant selection for a vaccine against urogenital schistosomiasis, Hematoshield

> **NIH NIH R41** · PAI LIFE SCIENCES, INC. · 2024 · $295,386

## Abstract

PROJECT SUMMARY
Schistosomiasis, caused by parasitic helminths, remains a major global health problem currently affecting over
250 million people in 78 countries with an additional 800 million people at risk of infection. Schistosoma
haematobium causes female genital schistosomiasis and urinary schistosomiasis resulting in bladder cancer if
left untreated. S. haematobium infection often results in formation of lesions within the vaginal tract of women,
often rendering them more susceptible to HIV coinfection. Since 2014, urogenital schistosomiasis is now being
actively transmitted in Southern Europe, a region previously thought to be schistosomiasis-free. Over the course
of 20 years, we have developed a potent schistosomiasis vaccine for S. mansoni, termed SchistoShield®,
targeting a functionally important antigen, Sm-p80, formulated using the TLR4-targeting adjuvant GLA-SE.
SchistoShield® has been exhaustively tested in numerous animal models and has consistently exhibited
protection at all parasite life cycle stages. We are near completion of a Phase 1 safety and dose-ranging human
clinical trial with SchistoShield® in the US – with no safety signals reported – and will begin Phase 1B trials in
Africa in Q3 of 2023 with a future Phase 2 trial in Africa to be funded by the Gates Foundation. We hypothesize
that a Sh-p80-based vaccine for S. haematobium (HematoShieldTM) could be developed using our extensive
experience with SchistoShield®, and that this homologous vaccine will provide superior protection against
urogenital schistosomiasis.
In this STTR we propose two Aims: (1) produce and release vaccine candidates and then to (2) Evaluate the
vaccine candidates in an animal model of urogenital schistosomiasis. Successful completion of these Aims will
be crucial identifying which candidate vaccine for this burdensome disease will be progressed into future current
Good Manufacturing Practice (cGMP) production, stability, potency, and toxicology testing as well as important
clinical trials for efficacy against S. haematobium.

## Key facts

- **NIH application ID:** 10818259
- **Project number:** 1R41AI181069-01
- **Recipient organization:** PAI LIFE SCIENCES, INC.
- **Principal Investigator:** Sean Alex Gray
- **Activity code:** R41 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $295,386
- **Award type:** 1
- **Project period:** 2024-01-03 → 2025-12-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10818259

## Citation

> US National Institutes of Health, RePORTER application 10818259, Antigen and adjuvant selection for a vaccine against urogenital schistosomiasis, Hematoshield (1R41AI181069-01). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10818259. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*